Nithya Desikan is an Operating Principal at Gurnet Point Capital, bringing more than 22 years of experience in pharmaceuticals and biotech operations and executive management, commercializing novel therapies and building start-up organizations. As a fully integrated member of the investment team, she is responsible for leading aspects of diligence that require operational expertise, identification of growth opportunities, and partnering with companies to drive post-close value creation. Since joining GPC, Nithya has been instrumental in the acquisition and transformation of Radius Health and Paratek Pharmaceuticals.
Prior to joining, Nithya was the Chief Operating Officer of Sionna Therapeutics, a company focused on development of novel therapies for Cystic Fibrosis. Prior to this role, she was the Chief Commercial Officer of Rhythm Pharmaceuticals from clinical-stage start-up to approval of their first product. Nithya joined Rhythm from Biogen, where in her 5-year tenure, she oversaw multiple launches and led cross-functional strategies for long-term value creation as Vice President and Asset Executive.
Nithya began her career with 12 years at Johnson & Johnson Company, launching brands in the US and abroad including: Xarelto®, Levaquin®, Topamax®, Ultracet®, and Velcade®. Ms. Desikan holds a BS in Material Science Engineering from the University of Florida.
Passion, accountability, and collaboration. At Paratek, we count on each other to build a company that saves lives. Learn more about life @Paratek.Explore Careers
Working in a collaborative environment to provide a life-saving therapy is not only empowering but inspiring. It is amazing to spend each day working with a team dedicated to our mission in creating positive stories for our patients and their caregivers.